KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Resmed (RMD) over the last 17 years, with Q4 2025 value amounting to $72.7 million.

  • Resmed's Change in Receivables rose 711.69% to $72.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $88.0 million, marking a year-over-year decrease of 3952.35%. This contributed to the annual value of $76.7 million for FY2025, which is 4289.16% down from last year.
  • Latest data reveals that Resmed reported Change in Receivables of $72.7 million as of Q4 2025, which was up 711.69% from -$30.0 million recorded in Q3 2025.
  • Over the past 5 years, Resmed's Change in Receivables peaked at $89.3 million during Q2 2021, and registered a low of -$48.8 million during Q4 2021.
  • Over the past 5 years, Resmed's median Change in Receivables value was $20.1 million (recorded in 2021), while the average stood at $22.5 million.
  • Over the last 5 years, Resmed's Change in Receivables had its largest YoY gain of 34727.22% in 2024, and its largest YoY loss of 45734.62% in 2024.
  • Resmed's Change in Receivables (Quarter) stood at -$48.8 million in 2021, then soared by 140.16% to $19.6 million in 2022, then surged by 36.85% to $26.8 million in 2023, then soared by 153.15% to $67.9 million in 2024, then rose by 7.12% to $72.7 million in 2025.
  • Its Change in Receivables stands at $72.7 million for Q4 2025, versus -$30.0 million for Q3 2025 and $5.2 million for Q2 2025.